Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C

Intervirology

Volumn 40, Issue 5-6, 1997, Pages 394-399

  Caselmann, Wolfgang H ^a,b   Eisenhardt, Stefan ^c   Alt, Michael ^b  

^a UNIVERSITY OF BONN   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Antisense oligodeoxynucleotides; Cell culture; Hepatitis C; In vitro translation; RNase H

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATE;

CELL CULTURE; ENDOCYTOSIS; ENDOSOME; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIPOPHILICITY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SIDE EFFECT; VIRUS GENE;

ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS;

EID: 2642638775     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150571     Document Type: Article

References (35)

1. Caselmann WH, Alt M: Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma, J Hepatol 1996;24(suppl 2):S61-S66.
2. Caselmann WH, Spengler U, Fischer HP, Saucrbruch T: Lebezrirrhosen als Prakanzcro-sen, Internist 1997;38:928-936
3. Poynard T, Bedossa P, Chevallicr M, Mathurin P, Lenimonier C, Trcpo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC and the Multicentcr Study Group: A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis, N Engl J Med 1995:332:1457-1462.
4. Chcmello L, Cavalletto L, Bemardincllo E, Guido M, Pontisso P, Alberti A: The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C, J Hepatol 1995;23(suppl 2):8-12.
5. Schalm SW, Hansen BE, Chcmello L, Bcllo-buono A, Brouwer J, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A: Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C, J Hepatol 1997:26:961-966.
6. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J: Ribavirin in the treatment of chronic hepatitis C unresposive to alfa interferon, J Hepatol 1993:19:408-412.
7. Ghosh MK, Cohen JS: Oligodeoxynucleotides as antisense inhibitors of gene expression, Prog Nucleic Acid Res 1992;42:79-126.
8. Milligan JF, Mattcucci MD, Martin JC: Current concepts in antisense drug design, J Med Chem 1993:36:1923-1937.
9. Stein CA, Cheng YC: Anliscnse oligonucleotides as therapeutic agents: Is the bullet really magical? Science 1993:261:1004-1012.
10. Tonkinson JL, Stein CA: Antisensc nucleic acids: Prospects for antiviral intervention, Antiviral Chem Chemother 1993:4:193-200.
11. Alper J: Oligonucleotides surge into clinical trials, Biotechnology 1993; 11:1225.
12. Wakita T, Wands JR: Specific inhibition of hepatitis C virus expression by antisense oligo-dcoxynuclcotidcs, J Biol Chem 1994:269: 14205-14210.
13. Alt M, Renz R, Hofschneidcr PH, Pauntgart-ner G, Caselmann WH: Specific inhibition of hepatitis C’ viral gene expression by antisensc phosphorothioate oligodeoxynucleotides in an in vitro test system, Hepatologv 1995:22:707-717.
14. All M, Renz, R, Hofschncider PH, Caselmann WH: Core-specific antisensc in phosphoro-thioatc oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation, Arch Virol 1997:142:598-599.
15. Kolykhalov AA, Agapov EV, Blight KJ, Mihal-ik K, Fcinstonc SM, Rice CM: Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA, Science 1997:277:570-574.
16. Honda M, Braun EA, Lemon SM: Stability of a stcm-loop involving the initiator AUG controls the efficiency of internal initiation of translation of hepatitis C virus RNA, RNA 1996:2: 955-968.
17. Kamoshita N, Tsukiyama-Kohara K, Kohara M, Nomoto A: Genetic analysis of internal ribosomal entry site on hepatitis C virus RNA: Implication for involvement of the highly ordered structure and cell type-specific transacting factors, Virology 1997;233:9-18.
18. Wang C, Le SY, Ali N, Siddiqui A: An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' noncoding region, RNA 1995;1:526-537.
19. Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R: Specific inhibition of human immunodeficiency virus type I replication by antisense oligonucleotides: An in vitro model for treatment, Proc Natl Acad Sci USA 1992:89:11209-11213.
20. Offensperger WB, Offensperger S, Waller E, Tcubner K, Igloi G, Blum HE, Gerok W: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleo-tidcs, EmboJ 1993; 12:1257-1262.
21. Gura T: Antisense has growing pains, Science 1995:270:575-577.
22. Agrawal S, Tcmsamani J, Galbraith W, Tang J: Pharmacokinetics of antisensc oligonucleotides, J Clin Pharmacokinct 1995;28:7-16.
23. Holt J: Antisense therapeutics, Mol Med Today 1996;2:184-185.
24. Benimctskaya L, Tonkinson JL, Koziolkicwicz M, Karwowski B, Guga P, Zeltser R, Stee W, Stein CA: Binding of phosphorothioate oligo-dcoxynuclcotidcs to basic fibroblast growth factor, recombinant soluble CD4. laminin and fibronectin is P-chirality independent, Nucleic Acids Res 1995:23:4239-4245.
25. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix, J Biol Chem 1995:270:2620-2627.
26. Fenncwald SM, Rando RF: Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides, J Biol Chem 1995:270: 21718-21721.
27. Brown DA, Kang SH, Gryaznov SM, DeDioni-sio L, Sullivan S, Xu X, Nerenberg Ml: Effect of phosphorothioate modification of oligo-dcoxynucleotides on specific protein binding, J Biol Chem 1994:269:26801-26805.
28. Miroshnichenko NA, Karpova OV, Morozov SY, Rodionova NP, Atabekov JG: Translation arrest of potato virus X RNA in Krebs-2 cell free system: RNase H cleavage promoted by complementary oligodeoxynucleotides, FEBS Lett 1988:234:65-68.
29. Haeuptle MT, Frank R, Dobberstein B: Translational arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polvpcptides of predetermined lenght, Nucleic Acids Res 1986.14:1427-1448.
30. Akhtar S, Juliano RL: Cellular uptake and intracellular fate of antisense oligonucleotides, TrendsinCell Biology 1992:2:139-144.
31. Stein CA, Tonkinson JL, Zhang L, Yakubov L, Gervasoni J, Taub R, Rotenberg RA: Dynamics of the internalization of phosphodiestcr oli-godcoxynuclcotides in IIL60 Cells, Biochemistry 1993:32:4855-4861.
32. Thierry AR, Dritschilo A: Intracellular availability of unmodified, phosphothioatcd and li-posomally encapsulated oligodeoxynucleotides for antisensc activity, Nucleic Acids Res 1992: 20:5691-5698.
33. Chiang M, Chan H, Zouncs M, Frcier S, Lima W, Bennett C: Antisense oligonucleotides inhibit intracellular adhesion molecule I expression by two distinct mechanisms, J Biol Chem 1991;266:18162-18171.
34. Crooke RM: In vitro toxicology and pharmacokinetics of antisense oligonucleotides, Anti-cancer Drug Res 1991:6:609-646.
35. Crooke ST: Progress in antisense therapeutics, Hematol Palhol 1995;2:59-72.